Draft:Mindset Health
Submission declined on 18 June 2026 by CopyleftEverything (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by IAmChaos 8 months ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
Comment: Long paragraph begins: "Nerva has been the subject of real-world studies" and lists studies conducted, but not their results or whether the studies were independently conducted. Come on, man. CopyleftEverything (talk) 02:43, 18 June 2026 (UTC)
| Type | Private |
|---|---|
| Industry | Digital therapeutics |
| Founded | 2018 |
| Founders | Alex Naoumidis, Chris Naoumidis |
| Headquarters | , Australia |
| Products | Nerva, Evia, Finito |
Mindset Health Pty Ltd is an Australian digital therapeutics company based in Melbourne that develops mobile applications delivering hypnotherapy-based programs for chronic health conditions.[1] It was founded by brothers Alex and Chris Naoumidis. Its main product, Nerva, delivers gut-directed hypnotherapy for irritable bowel syndrome.[2]
History
Mindset Health was founded by brothers Alex and Chris Naoumidis in 2018[1] and took part in the Y Combinator startup accelerator.[3] Its first product, Nerva, launched in June 2019.[1] The company raised about A$6.7 million in 2021[4] and a further A$17.8 million (US$12 million) in 2023 led by King River Capital, at a reported valuation of about A$77 million,[1] bringing its total funding to about A$24.5 million.[5] In May 2025 it acquired the assets of the U.S. digital therapeutics company Mahana Therapeutics.[6]
Products
Mindset Health's products include Nerva, for irritable bowel syndrome;[2] Evia, for menopausal hot flashes;[7] and Finito, for smoking cessation.[1]
Research
Nerva has been the subject of real-world studies presented at Digestive Disease Week (DDW). Researchers at Monash University reported on adherence and symptom outcomes in a cohort of about 195,000 users[8] and on outcomes in IBS patients with co-morbid inflammatory bowel disease.[9] Collaborators at Mount Sinai studied outcomes in patients with concurrent upper gastrointestinal symptoms,[10] and researchers at Mayo Clinic examined gender differences in early program attrition[11] and the addition of diaphragmatic breathing to gut-directed hypnotherapy.[12] An independent 2024 review in Clinical Gastroenterology and Hepatology identified Nerva as one of the few digital therapeutics for IBS with published clinical evidence.[13]
References
- ^ a b c d e Tess Bennett (2023-03-21). "Melbourne brothers build a $77m business from hypnotherapy apps". Australian Financial Review.
- ^ a b Anderson EJ, Peters SL, Gibson PR, Halmos EP (February 2025). "Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome". American Journal of Gastroenterology. 120 (2): 440–448. doi:10.14309/ajg.0000000000002921. PMID 38940439.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "Hypnosis for health? Investors have placed a $1.1 million bet on Mindset Health that it can work". TechCrunch. 2020-05-15.
- ^ "Evidence-based hypnotherapy app raises $6.7m". Australian Financial Review. 2021-06-25.
- ^ "Student startup Mindset Health raises $20 million". Monash University. 2023-03-22.
- ^ "Nerva Completes Mahana Therapeutics Acquisition to Expand Access to Digital Therapies for IBS" (Press release). Mindset Health. 2025-05-06 – via BioSpace.
- ^ Snyder M, Elkins GR (2024-03-14). "Characteristics of Users of a Digital Hypnotherapy Intervention for Hot Flashes: Retrospective Study". JMIR Formative Research. 8 e53555. doi:10.2196/53555. PMC 10979336. PMID 38483465.
- ^ Peters SL, Gibson PR, Halmos EP (2026). "Longitudinal improvement in adherence and efficacy of app-delivered gut-directed hypnotherapy". Gastroenterology. doi:10.1016/S0016-5085(26)04445-8.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Peters SL, Gibson PR, Halmos EP (2026). "Efficacy of app-delivered gut-directed hypnotherapy in irritable bowel syndrome patients with co-morbid IBD". Gastroenterology. doi:10.1016/S0016-5085(26)04437-9.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Noorani S, Brand D, Naoumidis C, Hall C, Smith MS, Jodorkovsky D, Luo Y (2026). "Brain-gut behavioral therapy program for IBS benefits patients with concurrent upper GI symptoms". Gastroenterology. doi:10.1016/S0016-5085(26)04658-5.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Hoeg A, Jin M, Wang I (2026). "Gender differences in early attrition during digitally delivered brain-gut behavioral therapy for IBS". Gastroenterology. doi:10.1016/S0016-5085(26)04738-4.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Jin M, Wang I (2026). "Enhanced irritable bowel syndrome symptom improvement with diaphragmatic breathing when added to gut-directed hypnotherapy". Gastroenterology.
- ^ Brenner DM, Ladewski AM, Kinsinger SW (2024). "Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome". Clinical Gastroenterology and Hepatology. 22 (2): 222–234. doi:10.1016/j.cgh.2023.09.012. PMID 37743035.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
- Reliable sources include: reputable newspapers, magazines, academic journals, and books from respected publishers.
- Unacceptable sources include: personal blogs, social media, predatory publishers, most tabloids, and websites where anyone can contribute.
Replace any unreliable sources with high-quality sources. If you cannot find a reliable source for the material, it should be removed.